Object before prose
Every page resolves to a defined intervention or study object, not a generic article topic.
Independent evidence reference
Know what was actually studied.
Leptox maps weight and metabolic interventions to the populations, endpoints, effects, evidence strength, and commercial status that define what the research can and cannot say.
StudyPopulationEndpointResult / effectEvidence levelIntervention
6intervention records
4landmark study records
0rankings or stacks
1evidence model
Intervention index
Different objects.
Same evidence frame.
Prescription medicines, supplements, and dietary patterns are not treated as interchangeable. Each record keeps the intervention type and evidence context visible.
Prescription medicationHigh evidence
Semaglutide
Randomized obesity trials show large average weight reductions, while treatment context, tolerability, discontinuation, and long-term use remain essential to interpretation.
Prescription medicationHigh evidence
Tirzepatide
SURMOUNT-1 found substantial mean weight reductions across randomized tirzepatide groups, with a dose-group gradient and gastrointestinal adverse events.
Prescription medicationHigh evidence
Metformin
Metformin has strong evidence for diabetes prevention in selected high-risk adults, but it is not equivalent to modern obesity pharmacotherapy and weight effects are usually modest.
Dietary supplement ingredientLow to moderate evidence
Berberine
Human trials and meta-analyses report mixed, generally small anthropometric effects. Product quality and study heterogeneity materially limit confidence.
Dietary intervention and supplement ingredientLow to moderate evidence
Psyllium / soluble fiber
Psyllium has plausible satiety and metabolic effects, but pooled weight estimates vary substantially with trial selection, population, and intervention design.
Dietary patternModerate evidence
High-protein dietary intervention
Higher-protein patterns can support weight-loss maintenance in some randomized settings, but the effect depends on energy balance, adherence, comparator diet, and population.
Landmark records
Trials behind
the headline.
Study pages separate design, population, endpoint, result, and interpretation so a single number cannot float free of its trial.
2021 · STEP 1Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine↗
2022 · SURMOUNT-1Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine↗
2002 · DPPReduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or MetforminNew England Journal of Medicine↗
2014 · DIOGENES extensionWeight Loss Maintenance on Ad Libitum Diets with High or Low Protein Content and Glycemic IndexInternational Journal of Obesity↗
Effect with context
Every result stays attached to the population, endpoint, comparator, and duration that produced it.
Limits stay visible
Null results, conflicting syntheses, and applicability limits receive the same prominence as positive effects.